Publish in this journal
Journal Information
Vol. 110. Issue 7.
Pages 520 (September 2019)
Vol. 110. Issue 7.
Pages 520 (September 2019)
Commentaries
DOI: 10.1016/j.adengl.2019.03.022
Full text access
Ixekizumab and Psoriasis in the Real World
Ixekizumab and Psoriasis in the Real WorldIxekizumab y psoriasis, ¿qué sucede en el mundo real?
Visits
...
I. Belinchón Romero
Servicio de Dermatología, Hospital General Universitario de Alicante-ISABIAL, Universidad Miguel Hernández, Alicante, Spain
Article information
Full Text
Bibliography
Download PDF
Statistics
Full Text

Psoriasis is an autoimmune disease with a complex pathogenesis in which the interaction of immunologic, genetic, and environmental factors results in different clinical forms, as well as different response to treatments.

In recent years, better understanding of the disease pathogenesis has enabled development of agents with new therapeutic targets, with excellent results in clinical trials, particularly in the case of moderate to severe forms of the disease. However, study of the treatment of psoriasis in clinical practice is necessary, as the patients included in clinical trials are not fully representative of those treated in this setting.1

Ixekizumab is a humanized recombinant biologic agent that targets IL-17A and that was recently approved for the treatment of moderate to severe plaque psoriasis. The efficacy and safety of the agent has been assessed in randomized clinical trials, although there is limited data on its use in routine clinical practice.2

In this issue, Magdaleno-Tapial et al.3 describe their study of the efficacy and safety of ixekizumab in patients with psoriasis in routine clinical practice in 2 hospitals in the Mediterranean region. This retrospective, observational study included 75 patients with moderate to severe psoriasis, some of whom had psoriasis in difficult-to-treat locations, and who received ixekizumab for a mean duration of 46 weeks. The authors demonstrated the efficacy and safety of the agent in routine clinical practice and, although this is not the first study in the clinical setting,4,5 it is the second largest series to date, and confirms the efficacy findings of previous studies. In addition, this study describes the efficacy of ixekizumab in difficult-to-treat sites such as the scalp, genital area, or palmoplantar region. The safety data are similar to those reported both in clinical trials and in studies in a clinical setting.

In summary, this study provides valuable information on the treatment with ixekizumab of patients with psoriasis vulgaris and psoriasis in difficult-to-treat sites in a clinical practice setting. Nevertheless, larger studies and registries of routine clinical practice will be needed to extend our knowledge in a real-world setting.

References
[1]
I. Garcia-Doval, G. Carretero, F. Vanaclocha, C. Ferrandiz, E. Daudén, J.L. Sánchez-Carazo, et al.
Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: Patients ineligible vs eligible for randomized controlled trials.
Arch Dermatol, 148 (2012), pp. 463-470
[2]
A. Blauvelt, M. Gooderham, L. Iversen, S. Ball, L. Zhang, N.O. Agada, et al.
Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3).
J Am Acad Dermatol, 77 (2017), pp. 855-862
[3]
J. Magdaleno-Tapial, R. Carmena-Ramón, C. Valenzuela-Oñate, J.M. Ortiz-Salvador, J. Sabater-Abad, P. Hernández-Bel, et al.
Eficacia y seguridad de ixekizumab en la práctica clínica habitual: estudio retrospectivo bicéntrico.
Actas Dermosifiliogr, (2019),
[4]
F. Diotallevi, A. Campanati, G. Radi, E. Molinelli, A. Offidani.
Ixekizumab for treatment of moderate to severe plaque psoriasis: Real world clinical experience.
G Ital Dermatol Venereol, (2018),
[5]
G. Deza, J. Notario, A. Lopez-Ferrer, E. Vilarrasa, M. Ferran, E. del Alcazar, et al.
Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: A multicentre retrospective study.
J Eur Acad Dermatol Venereol, 33 (2019), pp. 553-5598

Please cite this article as: Belinchón Romero I. Ixekizumab and Psoriasis in the Real World. Actas Dermosifiliogr. 2019;110:521.

Idiomas
Actas Dermo-Sifiliográficas (English Edition)

Subscribe to our newsletter

Article options
    NOTICE Undefined index: tipo (includes_ws_v2/librerias/html/item.php[1258])
    NOTICE Undefined index: tipo (includes_ws_v2/librerias/html/item.php[1258])
    NOTICE Undefined index: tipo (includes_ws_v2/librerias/html/item.php[1258])
    NOTICE Undefined index: tipo (includes_ws_v2/librerias/html/item.php[1258])
  • Additional material
Tools
NOTICE Undefined index: tipo (includes_ws_v2/librerias/html/item.php[1258])
NOTICE Undefined index: tipo (includes_ws_v2/librerias/html/item.php[1258])
NOTICE Undefined index: tipo (includes_ws_v2/librerias/html/item.php[1258])
NOTICE Undefined index: tipo (includes_ws_v2/librerias/html/item.php[1258])
Supplemental materials
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.